[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633264":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":26,"locations":35,"responsibleParty":55,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":26,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":38,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Umeå University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A - RT and SoC","EXPERIMENTAL","Local hypo fractionated adaptive radiotherapy to the bladder, 7 Gy in 3 fractions delivered every other day (eod) prescribed in addition to standard of care.",[13],"Radiation: Local hypo fractionated adaptive radiotherapy and Standard of Care",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm B - SoC","ACTIVE_COMPARATOR","Standard of care. All applicable palliative treatments, such as local RT, TURB, systemic anti-tumour treatments or other interventions\u002Ftreatments applicable according to treating physician are allowed.",[19],"Other: Standard of Care (Investigator Choice)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","Local hypo fractionated adaptive radiotherapy and Standard of Care","Patients randomized to the radiotherapy (RT) arm will receive external beam radiotherapy to the whole urinary bladder as well as Standard of Care.\n\nIntensity-modulated Radiotherapy will be delivered using an adaptive treatment strategy, permitting either:\n\n* Plan-of-the-day (PoD) adaptive radiotherapy using a predefined library of plans, or\n* Online adaptive radiotherapy (oART) with daily re-contouring and re-optimisation to the anatomy of the day.\n\nThe choice of adaptive strategy (PoD vs oART) and imaging modality (CBCT- or MR-based) is at institutional discretion, provided all protocol-specified target coverage objectives and organ-at-risk (OAR) constraints are met.\n\nThe prescribed dose is 21 Gy in 3 fractions of 7 Gy, delivered every other day.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Standard of Care (Investigator Choice)","All applicable palliative treatments associated with the Standard of Care, such as local RT, TURB, systemic anti-tumour treatments or other interventions\u002Ftreatments applicable according to treating physician are allowed",[15],[32],{"name":33,"affiliation":5,"role":34},"Karin Söderkvist, MD, PhD","PRINCIPAL_INVESTIGATOR",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Norrlands University Hosital","RECRUITING","Umeå","Västerbotten County","90185","Sweden","SE",{"type":45,"coordinates":46},"Point",[47,48],20.25972,63.82842,{"lat":48,"lon":47},[51],{"name":33,"role":52,"phone":53,"phoneExt":26,"email":54},"CONTACT","+46(0)90-785 00 00","karin.soderkvist@umu.se",{"type":34,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Karin Soderkvist","MD, PhD",[59],{"name":60,"class":61},"Västerbotten County Council, Sweden","OTHER_GOV","100633264","local-radiotherapy-for-urinary-bladder-cancer-in-patients-not-eligible-for-curative-treatment-100633264",false,"NCT07524426","Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment","Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment; a Prospective Randomized Phase III Trial.","LORUP","Inclusion Criteria:\n\n1. Oral and written consent\n2. Histologically confirmed MIBC with urothelial component\n3. Male or female participants ≥ 18 years old\n4. Deemed not to benefit from curative treatment at a multidisciplinary tumour conference (MDT) or having declined curative treatment of their own accord.\n\nExclusion Criteria:\n\n1. Clinical Fragility Scale score ≥8\n2. Previous pelvic RT with significant overlap\n3. Visceral or bone metastases on CT scan\n4. Multiple (\\>3) lymph node metastases with a measurement of \\>2 cm on CT scan\n5. Planed for systemic treatment at the time of inclusion.\n6. Local RT to the bladder indicated for the palliation of symptoms at the time of inclusion.","ALL","18 Years",{"count":73,"type":74},248,"ESTIMATED","INTERVENTIONAL",[77],"NA","The goal of this clinical trial is to improve the quality of life and prolong survival in bladder cancer patients unfit for curative treatment. The trial will compare the survival and symptoms of patients randomized to either local radiotherapy in addition to standard of care or standard of care alone.\n\nUsing modern radiotherapy techniques, including hypofractionation and image-guided treatment adaptation, the aim is to deliver a well-tolerated, time-efficient, and effective treatment strategy for these patients.\n\nThe trial collaborates with two ongoing exploratory biomarker studies collecting and analyzing potential biomarkers in urothelial bladder cancer. The hope is to provide biomarkers for prognosis and treatment response which is essential to ensure bladder cancer patients individualized treatment in the future, like those with breast and prostate cancer.",[80],"Bladder Cancer (BC)",[68,82,83,84,85,86],"Bladder cancer","local radiotherapy","adaptive radiotherapy","Patient Reported Outcomes","Overall survival","2026-06-05",{"date":89,"type":90},"2026-06-09","ACTUAL",{"date":92,"type":90},"2026-06-03",{"date":94,"type":74},"2034-06",{"name":5,"class":6},1]